In the last trading session, 2.02 million Ginkgo Bioworks Holdings Inc (NYSE:DNA) shares changed hands as the company’s beta touched 1.16. With the company’s per share price at $10.82 changed hands at -$0.61 or -5.34% during last session, the market valuation stood at $621.92M. DNA’s last price was a discount, traded about -495.19% off its 52-week high of $64.40. The share price had its 52-week low at $5.26, which suggests the last value was 51.39% up since then.
Analysts gave the Ginkgo Bioworks Holdings Inc (DNA) stock a consensus recommendation rating of Buy, calculated at a mean rating of 3.83. If we narrow down to specifics, the data shows that 2 out of 5 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended DNA as a Hold, 2 felt it is a Buy and 0 rated the stock as Underweight. Ginkgo Bioworks Holdings Inc’s EPS for the current quarter is expected to be -1.3.
Ginkgo Bioworks Holdings Inc (NYSE:DNA) trade information
Instantly DNA was in red as seen at the end of in last trading. With action -20.15%, the performance over the past five days has been red. The company’s shares are showing year-to-date upside of 10.18%, with the 5-day performance at -20.15% in the red. However, in the 30-day time frame, Ginkgo Bioworks Holdings Inc (NYSE:DNA) is -16.12% down.
The consensus price target for the stock as assigned by Wall Street analysts is 6.5, meaning bulls need a downside of -66.46% from its current market value. According to analyst projections, DNA’s forecast low is 4.35 with 12 as the target high. To hit the forecast high, the stock’s price needs a -10.91% plunge from its current level, while the stock would need to tank 59.8% for it to hit the projected low.
Ginkgo Bioworks Holdings Inc (DNA) estimates and forecasts
Year-over-year growth is forecast to reach -9.45% down from the last financial year.
Consensus estimates given by 5 financial analysts project the company’s revenue in the current quarter to hit an average of 44.43M. 4 analysts are of the opinion that Ginkgo Bioworks Holdings Inc’s revenue for the current quarter will be 44.24M. The company’s revenue for the corresponding quarters a year ago was 34.76M and 37.94M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 27.83%. The estimates for the next quarter sales put growth at 16.60%.
The 2025 estimates are for Ginkgo Bioworks Holdings Inc earnings to increase by 45.22%, but the outlook for the next 5-year period is at 43.25% per year.
Ginkgo Bioworks Holdings Inc (NYSE:DNA)’s Major holders
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 6.9327% or 138.96 million shares worth $46.46 million as of 2024-06-30.
Among Mutual Funds, the top two as of Sep 30, 2024 were Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. With 1.17 shares estimated at $12.65 million under it, the former controlled 2.59% of total outstanding shares. On the other hand, Vanguard Extended Market Index Fund held about 1.16% of the shares, roughly 526.35 shares worth around $5.7 million.
